A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).
A Single-Center Retrospective Study About Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen
Breast Cancer
DRUG: Eribulin-Based Regimen|DRUG: nab-paclitaxel based regimen|DRUG: Other Chemotherapy Regimen
Progression free surviva (PFS), The interval from the date of randomization to the first imaging confirmed progression of disease or death from any cause., up to 24 months|Overall survival (OS), The time interval from the date of randomization to death due to any cause., up to 24 months
Overall response rate (ORR), According to recist1.1 standard, the proportion of patients whose best remission was CR or PR accounted for the total number of evaluable patients, 12 months|Disease Control Rate (DCR), According to recist1.1 standard, the proportion of patients whose best remission was CR, PR or SD accounted for the total number of evaluable patients., 12 months|Incidence of adverse events, Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0), 12 months
Not provided